Richard Mason

CEO id Divide & Conquer Ltd; Co-founder of C21Med, The Foundation Institute for 21st Century Medicine

Divide & Conquer Ltd

Dr Richard Mason is CEO of Divide & Conquer, a Cambridge based company targeting tunneling nanotubules in cancer, and co-founder of C21Med, an initiative of venture capital firm Medicxi. He served as Head of Johnson & Johnson’s London Innovation Centre from October 2015 to April 2018, where he was responsible for innovation within the EMEA region. Prior to joining J&J, Richard was CEO of a venture-backed biotechnology startup, XO1 Ltd. until the company was acquired by J&J in 2015. Prior to that, he was Head of Strategy & BD and member of the Executive Leadership Team at BTG Plc. He was an Executive-in-Residence for Advent Venture Partners where he served as a turnaround CEO for several portfolio companies and prior to that he was a senior leader at Cambridge Antibody Technology. He trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine in the NHS before entering the biotechnology industry. He has a degree in immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is an Honorary Fellow in Healthcare Management.